

GUIDELINES FOR CLINICAL TRIAL APPLICATION IN RWANDA

APRIL, 2023

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

GUIDELINES DEVELOPMENT HISTORY

DRAFT ZERO BY CONSULTANTS	20 th May 2018
ADOPTION BY RWANDA FDA	18 th September 2020
STAKEHOLDERS CONSULTATION	14 th October 2020
ADOPTION OF STAKEHOLDERS' COMMENTS	25 th November 2020
DATE FOR COMING INTO EFFECT	11 th April 2023

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

DOCUMENT REVISION HISTORY

Date of	Revision	Changes made and/or reasons for revision	
revision	number	0	
05/02/2021	00	First issue	
18/06/2021	01	 Provisions for expedited review of Clinical Trial Application (CTA) were included; Provisions for application, review, and approval of clinical Trial during health emergencies; Provisions for reliance pathway approval as the non-routine procedure for clinical trial authorization in Rwanda were incorporated; Requirements for renewal of clinical trial Authorizations were included; The flowchart for the clinical trial was revised and included; The table revision history was included; 	
		7. Necessary editorial changes and formatting were made.	
01/04/2023	02	 The reference number was changed from DIS/GDL/033 to FDISM/PVSM/GDL/005 Rev_2 as per the current SOP on document control Provisions for expedited review of CTA were moved to the Guidelines for Review and Approval of CTAs; Provisions for the application, review, and approval of clinical trials during health, emergencies were moved to the Guidelines for Review and Approval of CTA; Provisions for reliance pathway approval as the non-routine procedure for clinical trial authorization in Rwanda were moved to the Guidelines for Review and Approval of CTAs; Criteria to be followed for accepting evidence of GMP compliance for imported IMPs were included; Section 1.3 regarding the review process was moved to the guidelines for the Review and Approval of CTA; Critical requirements for acceptance of CTA were included; Format and content of the CTA updated; Requirements for renewal were included; 	

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

FOREWORD

Rwanda Food and Drugs Authority (Rwanda FDA) is a regulatory body established by Law N° 003/2018 of 09/02/2018, specifically in article 8, paragraphs 7 and 12 to regulate and inspect clinical trials. In reference to the provisions of the technical regulation N° FDISM/PVSM/TRG/001 Rev_2 governing the conduct of clinical trials, the Authority Issues *Guidelines N*° FDISM/PVSM/GDL/005 Rev_2 on clinical trial application in Rwanda.

These guidelines have been developed to provide guidance to the applicants and the Authority in preparation and managing applications for clinical trials. These guidelines were developed in reference to the existing guidelines the of World Health Organization (WHO) and the International Conference on Harmonization of Technical Requirements for Good Clinical Practices (ICH E6) and other available literature.

The Authority acknowledges all the efforts of key stakeholders who participated in the development, review and validation of these guidelines.

Dr. Emile BIENVENU Director General

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

TABLE OF CONTENTS

GUIDELINES DEVELOPMENT HISTORY	2
DOCUMENT REVISION HISTORY	3
FOREWORD	4
TABLE OF CONTENTS	5
ACRONYMS AND ABBREVIATIONS	6
1. INTRODUCTION	.12
1.1 Scope of these Guidelines	.12
1.2 General Information	.13
2. CLINICAL TRIAL APPLICATION PROCESS AND REQUIREMENTS	.14
2.1 Requirements for Pre-Submission Meeting Application	.14
2.2 Clinical Trial Application requirements	.14
2.2.1 Submission of clinical trial application dossier	.17
2.2.2 Clinical Trial Application Fees	
2.2.3 Clinical Trial Protocol	.17
2.2.4 Investigator's Brochure	.18
2.2.5 Informed Consent and Assent	.18
2.2.6 Ethical Clearance	.18
2.2.7 Insurance cover of trial participants.	.18
2.2.8 Data and Safety Monitoring Board/Committee (DSMB/C)	.18
2.2.9 Materials Transfer Agreement (MTA)	. 19
2.2.10 Investigational Product (IP) Dossier	. 19
2.2.11 Evidence of Good Manufacturing Practices (GMP) compliance	. 19
3.0. Requirements for amendment of approved clinical Trial	.20
3.1 Substantial amendments	.20
3.1.1 Non-substantial amendments	.21
3.2 Filing a Clinical Trial Application Amendment	.21
3.3 Requirements for Renewal of Clinical Trial Authorization	.21
3.4 Application for import of Investigational Products	. 22
3.5 Requirements for labelling and blinding of Investigational Products	. 22
APPENDIX I: Clinical Trial Application Process Flow chart	. 24
APPENDIX II: Phases of Clinical Trials	.25
APPENDIX III: List of possible amendment to an approved trial	
ENDORSEMENT OF THE GUIDELINES	. 29
ANNEX-I: Clinical Trial Application Form (CTA)	. 30
ANNEX- II: Clinical Trial Protocol Format	. 32
ANNEX-III: Joint Declaration for Sufficient Funds	.40
ANNEX-IV: Declaration by principal investigator or co-investigator	
ANNEX-V: Investigational Product Quality Overall Summary Template	.43
ANNEX-VI: Protocol Pre-Submission Synopsis	
ANNEX-VII: Clinical Trial Amendment Application Form (CTA-A)	. 54

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ACRONYMS AND ABBREVIATIONS

APIActive Pharmaceutical ProductAVAREFAfrican Vaccine Regulatory ForumCIOMSCouncil of International Organization for Medical ScienceCROContract Research OrganizationCRFCase report formCTAClinical Trial ApplicationCTAClinical Trial Application for AmendmentDSMBData Safety and Monitoring BoardEUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda FOARwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious AdverseWHO:World Health Organisation	AE	Adverse Event
CIOMSCouncil of International Organization for Medical ScienceCROContract Research OrganizationCRFCase report formCTAClinical Trial ApplicationCTAClinical Trial Application for AmendmentDSMBData Safety and Monitoring BoardEUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	API	Active Pharmaceutical Product
CROContract Research OrganizationCRFCase report formCTAClinical Trial ApplicationCTA-AClinical Trial Application for AmendmentDSMBData Safety and Monitoring BoardEUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	AVAREF	African Vaccine Regulatory Forum
CRFCase report formCTAClinical Trial ApplicationCTA-AClinical Trial Application for AmendmentDSMBData Safety and Monitoring BoardEUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	CIOMS	Council of International Organization for Medical Science
CTAClinical Trial ApplicationCTA-AClinical Trial Application for AmendmentDSMBData Safety and Monitoring BoardEUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda FDARwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	CRO	Contract Research Organization
CTA-AClinical Trial Application for AmendmentDSMBData Safety and Monitoring BoardEUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSUSARsSuspected Unexpected Serious Adverse	CRF	Case report form
DSMBData Safety and Monitoring BoardEUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda FDASafesSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	СТА	Clinical Trial Application
EUALEmergency Use Assessment and Listing ProcedureFPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	СТА-А	Clinical Trial Application for Amendment
FPPFinished pharmaceutical ProductGCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	DSMB	Data Safety and Monitoring Board
GCPGood Clinical PracticeGLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDAQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	EUAL	Emergency Use Assessment and Listing Procedure
GLPGood Laboratory PracticeGMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSUSARsSuspected Unexpected Serious Adverse	FPP	Finished pharmaceutical Product
GMPGood Manufacturing PracticeIBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDASerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	GCP	Good Clinical Practice
IBInvestigator's BrochureICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	GLP	Good Laboratory Practice
ICHInternational Conference on HarmonizationICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDASerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	GMP	Good Manufacturing Practice
ICFsInformed Consent FormsIRBInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	IB	Investigator's Brochure
IRBInstitutional Review BoardIPInstitutional Review BoardIPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	ICH	International Conference on Harmonization
IPInvestigational ProductMTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	ICFs	Informed Consent Forms
MTAMaterial Transfer AgreementNDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	IRB	Institutional Review Board
NDANew Drug ApplicationQOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	IP	Investigational Product
QOSQuality Overall SummaryPIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	MTA	Material Transfer Agreement
PIPrincipal InvestigatorRNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	NDA	New Drug Application
RNECRwanda National Research Ethics CommitteeRwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	QOS	Quality Overall Summary
Rwanda FDARwanda Food and Drugs AuthoritySAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	PI	Principal Investigator
SAEsSerious Adverse EventsSmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	RNEC	Rwanda National Research Ethics Committee
SmPCSummary of product characteristicsSUSARsSuspected Unexpected Serious Adverse	Rwanda FDA	Rwanda Food and Drugs Authority
SUSARs Suspected Unexpected Serious Adverse	SAEs	Serious Adverse Events
1 1	SmPC	Summary of product characteristics
WHO: World Health Organisation	SUSARs	Suspected Unexpected Serious Adverse
	WHO:	World Health Organisation

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

GLOSSARY

In these guidelines, unless the context otherwise states:

'Applicant'' means the Sponsor or Principal Investigator or any other authorized person to apply for clinical trial and issued a Clinical Trial Certificate. The applicant shall therefore be responsible for signing the application form.

"Authority" Means Rwanda Food and Drugs Authority or its acronym "Rwanda FDA", established under the article 2 of the Law N° 003/2018 of 09/02/2018.

"Amendment" A written description of a change(s) to or formal clarification of a protocol.

"Applicable Regulatory Requirement(s)" Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

"Assent" A process by which a child, who is capable of understanding voluntarily, confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the child's decision to participate. Assent is documented by means of a written, signed and dated assent form from the child. As part of the assent process, parents and guardians must give informed consent.

"Audit" A systematic and independent examination of trial related activities and documents to determine whether the evaluated trial related activities were conducted, and the data were recorded, analyzed and accurately reported according to the protocol and applicable standard operating procedures (SOPs), the Authority and ICH-GCP requirement(s).

"Blinding/Masking" A procedure in which one or more parties to the trial are kept unaware of the treatment assignment(s). Single-blinding usually refers to the participant(s) being unaware; and double-blinding usually refers to the participant(s), investigator(s), monitor, and, in some cases, data analyst(s) being unaware of the treatment assignment(s).

"Case Report Form" A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each study participant.

"Clinical Trial" Any investigation in human study participants intended to discover or verify the clinical, pharmacological and/or other pharmacodynamics effects of an investigational product(s) and/or to identify any adverse reactions to an investigational product(s) and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous.

"Clinical Trial Report" A written description of a trial/ study of any therapeutic, prophylactic or diagnostic agent conducted in human study participants in which the clinical and statistical description, presentations and analyses are fully integrated into a single report.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

"Contract" A written, dated and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations and, if appropriate, on financial matters. The protocol may serve as the basis of a contract.

"Data and Safety Monitoring Board" An independent data monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints and to recommend to the sponsor whether to continue, modify, or stop a trial.

"Documentation" All records, in any form (including, but not limited t, written, electronic, magnetic, and optical records, and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions taken.

"Essential Documents" Documents that individually and collectively permit evaluation of the conduct of a study and the quality of the data produced.

"Ethical Clearance" An authorization to conduct a clinical trial issued by the Rwanda National Research Ethics Committee (RNEC) based on ethical issues related to trials involving human participants in Rwanda.

"Good Clinical Practice" A standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provide assurance that the data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial/study participants are protected.

"Good Manufacturing Practice (GMP)" The part of pharmaceutical quality assurance which ensures that products are consistently produced and controlled to quality standards appropriate to their intended use and as required by the marketing authorization.

"Impartial witness" A person, who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the participant or the participant's legally acceptable representative cannot read, and who reads the Informed Consent Form and any other written information supplied to the participant.

"Informed Consent" A process by which a study participant voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the study participant's decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.

"Inspection" The act of conducting an official review of documents, facilities, records, and any other resources that are deemed by the Authority to be related to the clinical trial and that may be located at the site of the trial, at the sponsor's and/or CRO's facilities or at other establishments deemed appropriate by the Authority.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

'Investigational Product" A pharmaceutical product in form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use. These include but are not limited to pharmaceutical products, biologicals (e. vaccines), medical devices.

"Investigator" A physician, dentist, or another qualified person who conducts a clinical trial at a trial site. See also Sub-investigator.

"Investigator's Brochure" A compilation of the clinical and non-clinical data on the investigational product(s), which is relevant to the study of the investigational product(s) in human study participants. *"Legal representative"* The name given to describe the executor, administrator or the person who looks after another person's affairs.

"Materials Transfer Agreement" An MTA is a written contract that governs the transfer of tangible research materials or biological samples between parties.

"Multi-centre Trial" A clinical trial conducted according to a single protocol but at more than one site, and therefore, carried out by more than one investigator.

"Notifications" means changes to the details of a trial that have no significant implications for the study participants, conduct, management, and scientific value of the research

"Phase I trials" These are the first trials of a new active ingredient or new formulations in man, often carried out in healthy volunteers. Their purpose is to establish a preliminary evaluation of safety and a first outline of the pharmacokinetic and, where possible, pharmacodynamics profile of the active ingredient.

"Phase II trials" These trials are performed with a limited number of study participants and are often, at a later stage, of a comparative (e.g. placebo-controlled) design. Their purpose is to demonstrate therapeutic activity and to assess the short-term safety of the active ingredient in patients suffering from a disease or condition for which the active ingredient is intended. This phase also aims at the determination of appropriate dose ranges or regimens and (if possible) clarification of dose-response relationships in order to provide an optimal background for the design of extensive therapeutic trials.

"Phase III trials" Trials in larger (and possibly varied) patient groups with the purpose of determining the short and long-term safety/efficacy balance of formulation(s) of the active ingredient, and of assessing its overall and relative therapeutic value. The pattern and profile of any frequent adverse reactions must be investigated and special features of the product must be explored (e.g. clinically relevant investigation product interactions, factors leading to differences in effect such as age). These trials should preferably be of a randomized double-blind design, but other designs may be acceptable, e.g. long-term safety studies. Generally, the conditions under which these trials are carried out should be as close as possible to normal conditions of use.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

"Phase IV studies" Studies performed after marketing of the pharmaceutical product. Trials in phase IV are carried out on the basis of the product characteristics on which the marketing authorization was granted and are normally in the form of post-marketing surveillance, or assessment of therapeutic value or treatment strategies. Although methods may differ, these studies should use the same scientific and ethical standards as applied in pre-marketing studies. After a product has been placed on the market, clinical trials designed to explore new indications, new methods of administration or new combinations, etc. are normally considered as trials for new pharmaceutical products.

"*Pharmaceutical product*" any substance capable of preventing, treating human or animal diseases and any other substance intended for administration to a human being or an animal in order to diagnose diseases, restore, correct or carry out modification of organic or mental functions.

"Placebo" An inactive substance or sham form of a therapy administered as a control in testing experimentally or clinically the efficacy of a biologically active preparation or procedure.

"Pre-clinical Studies" Biomedical studies not performed on human study participants.

"Principal Investigator" A person responsible for the conduct of the clinical trial at a trial site who is a physician, dentist or other qualified person, resident in Rwanda and a member of good standing of a professional body. If a trial is conducted by a team of individuals at a trial site, the principle investigator is the responsible leader of the team. See also Sub-investigator.

"Protocol" A document that describes the objective(s), design, methodology, statistical considerations and organization of a trial. The protocol usually also gives the background and rationale for the trial but these could be provided in other protocol referenced documents.

"Protocol Amendment" A written description of change(s) to or formal clarification of a protocol.

"Randomization" The process of assigning trial study participants to treatment or control groups using an element of chance to determine the assignments in order to reduce bias.

"Reliance" is the act whereby the regulatory Authority in one jurisdiction may take into account and give significant weight to regulatory work performed by another regulatory or trusted institution for purposes of reaching its own regulatory decisions.

"Source Data" All information in original records and certified copies of original records of clinical findings, observations or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies).

"Sponsor" An individual, company, institution or organization which takes responsibility for the initiation, management and/or financing of a clinical trial.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

"Sponsor-Investigator" An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a study participant. The term does not include any person other than an individual (e.g., it does not include a corporation or an agency). The obligations of a sponsor-investigator include both those of a sponsor and those of an investigator.

"Standard Operating Procedures (SOP)" Detailed written instructions to achieve uniformity of the performance of a specific function.

"*Substantial amendment*": means change to the terms of the protocol or any other trial supporting documentation that is likely to have significant impact and affect the safety and integrity of trial participants, the scientific value of the research, the conduct or management of the research, and the quality or safety of any investigational medicinal product used in research.

"The law" means Law No. 003/2018 of 09/02/2018 establish Rwanda Food and Drugs Authority and Determining its Mission, Organization and Function.

"Trial participant" An individual who participates in a clinical trial either as a recipient of the investigational medicinal product(s) or as a control.

"*Trial Site*" The location(s) where trial-related activities are actually conducted.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

1. INTRODUCTION

Clinical trials are planned scientific investigations conducted in humans and animals to gather information on the safety and efficacy of medical products and health technologies. Such experiments involve the administration of investigational products in patients, healthy volunteers or animal species to generate data which can later on be used for marketing authorization of a product. The regulatory authority mandated to regulate the conduct of clinical trials in Rwanda is Rwanda Food and Drugs Authority.

These guidelines highlight requirements that need to be followed by Investigators and Sponsors when submitting their applications for approval to conduct clinical trials in Rwanda. Good Clinical Practice (GCP) principles and other ethical considerations are also detailed with the aim of ensuring that trial participants are protected and safeguarded against any harm that might arise as a result of participating in clinical trials.

The guidelines are arranged in a modular format as adopted from the ICH guidelines to allow consistent and uniform documentation of submissions. These will in-turn pave-a-way for speedy assessment of applications by the Authority and ultimately decisions on approval/non-approval based on clear and transparent criteria.

These guidelines have been developed and updated to assist applicants to compile clinical trial application dossier for authorization to conduct clinical trials in Rwanda. The clinical trial application dossier is divided into three different modules as follows:

- a) Module I: administrative and protocol-related information about the trial;
- b) **Module II:** Information related to the Quality (Chemistry, Manufacturing, and Control) summaries about the investigational products to be used in the proposed trial;
- c) Module III: Other Supporting Information.

Applicants should submit their applications as per the Modules. The information in these Modules should be presented in relevant sections and should not be modified.

1.1 Scope of these Guidelines

The scope of these guidelines applies to the regulatory requirements for clinical trial applications including bioequivalence studies to the Authority for Authorization prior to initiation. They are addressed to investigators, the pharmaceutical industry, Clinical Research Organizations (CROs) and sponsors of clinical trials, whether for academic purposes or for the generation of data, intended for inclusion in the regulatory submissions for investigational products.

A new application for clinical trial conduct in Rwanda is required for the following categories of products/ circumstances:

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

- 1. New Medicines, Vaccines and other biological products, herbal medicines, cosmetics, medical devices and diagnostics for which safety/efficacy profile has not been determined;
- 2. A clinical investigation of a non-CE-marked (Certificate of European) medical device in the following circumstances:
- 3. The introduction of a completely new concept of device into clinical practice where components features and/or methods of action, are previously unknown;
 - a) Where a device incorporates materials previously untested in humans, coming into contact with the human body or where existing materials are applied to a new location in the human body, in which case compatibility and biological safety will need to be considered;
 - b) Where a device, either CE-marked or non-CE-marked, is proposed for a new purpose or function;
 - c) Where in vitro and/or animal testing of the device cannot mimic the clinical situation
- 4. Registered medicines, vaccines and other biological products, herbal medicines, cosmetics, medical devices and diagnostics where the proposed clinical trials are outside the conditions of approval. These may include changes to:
 - a) Indications and clinical use
 - b) Target patient or animal population(s) e.g. age group and race.
 - c) Routes of administration
 - d) New dosage scheme/regimen.
 - e) The intended use of a device(s)
 - f) New combination drug products
 - g) New drug delivery/release system
- 5. Academic clinical trials: clinical trial not funded by pharmaceutical or Biotechnology Company for commercial ends but by public-good agencies (usually universities or medical trusts) to advance medicine.

1.2 General Information

All applications and supporting documents shall be in one of the official languages used in Rwanda. Data shall be presented in A4 papers either hard copy or electronic format using New Times, font 12. The clinical trial application documents shall be submitted in modules I, II, and III in hard or soft copies in searchable PDF. Extension sheets, tables, diagrams and other supporting documents shall as far as possible be of the same size, well annotated, numbered and appropriately cross-referenced. The information/data must be compiled in accordance with these guidelines. In case the information is required in the application forms its location shall be cross-referenced in the submission.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

2. CLINICAL TRIAL APPLICATION PROCESS AND REQUIREMENTS

2.1 Requirements for Pre-Submission Meeting Application

An application for a pre-submission consultation meeting is optional and shall be made by the sponsor or Principal investigator who submit to the Authority following documents:

- a) The cover letter requesting the pre-submission meeting;
- b) A brief synopsis of the proposed trial protocol as per ANNEX-VI
- c) A list of preliminary questions to be discussed in the meeting;

The Authority will acknowledge the receipt of the application and will confirm the meeting date, venue and time of meeting within fifteen (15) calendar days after the receipt of meeting request.

After the meeting, the sponsor should prepare and send to the Authority a written record of the discussions and conclusions of the meeting within 14 calendar days.

2.2 Clinical Trial Application requirements

A Clinical Trial Application for conducting clinical trials in Rwanda including bioavailability studies should be made to the Authority prior to the initiation. The content and format of clinical trial application is composed of three modules:

- a) Module I: Administrative and protocol related information about the trial;
- b) **Module II**: Information related to the Quality (Chemistry, Manufacturing and Control) summaries about the investigational products to be used in the proposed trial;
- c) Module III: Other Supporting Information

Administrative Information and Protocol Related Information		
Administrative Information		
Signed and dated Cli	Signed and dated Clinical Trial Application Cover letter	
Signed and dated clin	Signed and dated clinical trial application form-ANNEX-I	
Valid Ethical Clearar	Valid Ethical Clearance Certificate from Rwanda National Ethics Committee	
Curriculum vitae (CV	Curriculum vitae (CVs) of Principal investigator(s) and Co-investigator(s)	
Copy of Valid GCP Certificates for both Principal Investigator(s) and co-Principal investigator (s)		
Signed and dated Joint declaration between Sponsor & Principal Investigator for sufficient funds in the prescribed format (ANNEX-III)		
Signed and dated declarations by the Principal investigator and/or Co-investigators (ANNEX-IV)		
FDISM/PVSM/GDL/005 Revision Date: 01/04/2023 Review Due Date: 10/04/2026		
n No.: 02 Approval date: 05/04/2023 Effective Date: 11/04/2023		Effective Date: 11/04/2023
	Administrative Info Signed and dated Cli Signed and dated clin Valid Ethical Clearan Curriculum vitae (CV Copy of Valid GCP investigator (s) Signed and dated Jo sufficient funds in th Signed and dated dec (ANNEX-IV)	Administrative Information Signed and dated Clinical Trial Application Cover I Signed and dated clinical trial application form-AN Valid Ethical Clearance Certificate from Rwanda N Curriculum vitae (CVs) of Principal investigator(s) Copy of Valid GCP Certificates for both Principal investigator (s) Signed and dated Joint declaration between Spons sufficient funds in the prescribed format (ANNEX-Signed and dated declarations by the Principal inve (ANNEX-IV) DISM/PVSM/GDL/005 Revision Date: 01/04/2023

The contents of each module of clinical trial application dossier are summarized in the table provided below:

1.1.8	Valid Local Insurance Policy Covering trial participants			
1.1.9	Signed and dated Sponsor/ Principal investigator contractual Agreement			
1.1.10		etters of Access authorizing Authority to access related files (Drug Master Files,		
	Site Reference Files)	Site Reference Files) must be submitted		
1.1.11	Clinical Trial Site Ag	reement/contract		
1.1.12	Collaborative note fr	om Rwanda Biomedical Cente	r for clinical trial on products	
	used under public he	alth programs(HIV,TB,Malaria	,etc),if applicable	
1.1.13		sions and conclusions of the pr	_	
	_	nce with the Authority, if applic		
1.1.14		uthorities to which the same a	pplication has been submitted	
	and details of decision	,		
1.1.15		of the trial with a WHO recog		
		y be registered with the Pan A	frican Clinical Trials Registry	
1.1.16	(PACTR)	of prescribed fees		
	Evidence of payment of prescribed fees			
1.2	Clinical Trial Proto	nical Trial Protocol-related Information		
1.2.1	A copy of the final proposed protocol(s), including the version number. The trial			
	protocol must be signed by the sponsor and the investigator prior to the start of the			
	clinical trial (ICH E6 8.2.2)			
1.2.2	A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda			
	signed and stamped by the Rwanda National Ethics Committee that includes a			
	statement regarding the risks and anticipated benefits to the clinical trial participants			
1.2.3	as a result of their participation in the clinical trial Copy of Participant Information Leaflet (PIL)			
1.2.3		py of Case Report Forms (CRFs) to be used for data collection		
1.2.5		ing plan including training and updating of staff involved in the trial		
1.2.6	Good Clinical Laboratory Practice (GCLP) accreditation certificate			
1.2.0		• , ,		
1.2.7	-	Signed Charter of DSMB and CVs of Members if applicable Signed and dated Materials Transfer Agreement (MTA) if applicable		
Module II		I to the Quality of Investigation	· · · · ·	
11200001012	(Chemistry, Manufacturing, and Control Summaries)			
2.1	Investigational Product (IP) Dossier containing the Quality Overall Summary and			
	showing the chemistr	y, manufacture, and control (Cl	MC) as per Common technical	
	document (CTD) format in ANNEX-V, non-clinical data, and Data from previous			
	clinical use (if applicable). Non-clinical data reports should be included in the			
		uirements in the latest version of		
2.2		nt Investigator's Brochure (IB),		
	with up-to-date safety	y, non-clinical, and available cli	inical data	
Doc. No : FDI	Doc. No.: FDISM/PVSM/GDL/005 Revision Date: 01/04/2023 Review Due Date: 10/04/2026			
Revision NO.:	Revision No.: 02 Approval date: 05/04/2023 Effective Date: 11/04/202		Effective Date: 11/04/2023	

2.3	Copy of valid Good Manufacturing Practice (GMP) Certificate or Confirmation document of the authority that the manufacturer complies with PIC/S or GMP inspection report or ISO Certificate for medical device/IVD
2.4	A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels
2.5	Investigational product package Insert/s for mark if applicable
2.6	Mock-up labels for the Investigational Product(s)
2.7	Copy of the summary of product characteristics (SmPC) or a copy of the certificate of pharmaceutical product (COPP) of the investigational products if applicable
2.8	Copy of Certificate of analysis for the batches of the investigational products to be used in a clinical trial if applicable
2.9	Composition of the placebo (placebo-controlled trials, information on the placebo is also required including a description of the manufacturing process, a qualitative and quantitative list of ingredients, specifications, batches, stability and facility information) or diluent if applicable
2.10	Copy of the import authorization in case the investigational product is not imported directly to the trial site
Module III	Other Supporting Information
3.1	Additional supporting quality information such as publications
3.2	Literature References

Note: Non-compliance and non-conformity to the regulatory requirements prescribed in these guidelines shall lead to the clinical trial application rejection. The Clinical Trial Application shall be accepted for review if more than 70% of the applicable required documents are provided. This shall include but not be limited to the signed, dated application letter and forms, duly signed protocol, updated IB, proof of payment of applicable fees, declarations, and agreement between the sponsor and principal investigator. Therefore, sponsors, investigators and Clinical Research Organizations (CROs) are encouraged to submit a completed clinical trial application dossier to avoid rejection and delays in the review process.

Application for compassionate use of unauthorized investigational products shall follow requirements set out in the latest version of AVAREF Guidance and Considerations on Compassionate Use Access Application for compassionate use of unauthorized investigational products shall follow requirements set out in the latest version of AVAREF Guidance and Considerations on Compassionate Use Access.

Additional requirements for medical devices clinical trials

In addition, the following documentation will be required for clinical trials of medical devices:

1) Device description, intended use, design and User manual of the device

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

- 2) Marketing authorization from other countries if applicable
- 3) Risk assessment and standard list
- 4) Sterilization validation certificate if applicable
- 5) Electrical safety certificate if applicable
- 6) Software as medical device classification if applicable.

7.1 **Conduct of clinical trials involving medical devices and diagnostics**

The design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the safety or performance of medical devices should be as prescribed in the ISO 14155-2011 (en) Clinical investigation of medical devices for human subjects – Good Clinical Practice and ISO14971: 2007 Medical devices – application of risk management to medical devices guidelines

2.2.1 Submission of clinical trial application dossier

The clinical trial application dossier to the following address:

Director General Rwanda Food and Drugs Authority Email: <u>info@rwandafda.gov.rw</u> P.O. Box 1948 Kigali, Rwanda.

2.2.2 Clinical Trial Application Fees

An application shall be accompanied by a non-refundable application fee as prescribed in the Regulations No CBD/TRG/004 related to regulatory service tariff/fees and fines. The application fees should be paid on the Rwanda FDA accounts:

- a) National Bank of Rwanda (BNR): 1000047658 entitled "Rwanda FDA" in Frw
- b) National Bank of Rwanda (BNR): 1000047666 entitled "Rwanda FDA" in USD Swift code is: BNRRWRWRW
- c) Bank of Kigali (BK): 100025143684entitled "Rwanda FDA" in Frw
- Bank of Kigali (BK): 100025143765 entitled "Rwanda FDA" in USD Swift code is: BKIGRWRW

Note: The authority is not reliable for transfer charges.

2.2.3 Clinical Trial Protocol

The content and format of the clinical trial protocol and its amendments should comply with the requirements set out in the latest version of the ICH GCP guidelines. Site specific information may be provided on separate protocol page(s), or addressed in a separate agreement for multicentre clinical trials. The protocol and its amendment should be those reviewed by the Rwanda National Ethics Committee and signed by the both sponsor and principle investigator. The clinical trial protocol template (ANNEX-II) is provided as a guide capturing key section of ICH GCP guidelines.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

2.2.4 Investigator's Brochure

The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the trial of the product(s) in human participants. The content and format of the Investigator's Brochure (IB) and its updates should comply with the requirements set out in the latest version of the ICH GCP guidelines. The approved summary of product characteristics (SmPC) may be used in place of the Investigational Brochure (IB) if the investigational product is marketed and is used according to the terms of the marketing authorization. If the conditions of use in the clinical trial differ from those authorized, the SmPC should be supplemented with a summary of relevant non-clinical and clinical data that support the use of the IP in the clinical trial.

2.2.5 Informed Consent and Assent

The informed consent informed consent should comply with regulatory requirements and abide with ICH GCP guidelines and the ethical principles that have their origin in the Declaration of Helsinki. Note that, the language used in the ICF shall be in English, French and Kinyarwanda and approved by Rwanda National Ethics Committee.

2.2.6 Ethical Clearance

A valid Ethical Clearance certificate issued by RNEC is required for all phases of clinical trials. The Authority shall give its position after the applicant has submitted ethical clearance. The Authority shall allow parallel submission of clinical trial applications to facilitate the sponsor and principal investigators. In this case, the evidence of submission to RNEC shall be required and any change made to the protocol by RNEC will be submitted to the Authority.

2.2.7 Insurance cover of trial participants.

All trial participants must be satisfactorily insured against possible injuries that must arise during the conduct of clinical trial. The valid evidence insurance policy issued by the local insurance company for participants shall be submitted to Authority prior to the study initiation.

The insurance certificate shall contain at least the following elements:

- a) policy number,
- b) starting date and expiry Date,
- c) insured (Policy Holder/Sponsor),
- d) title of insured protocol or protocol number,
- e) number of trial participants and
- f) List all events that are covered by the insurance policy e.g. deaths, permanent and temporary impairment of health conditions, etc.

2.2.8 Data and Safety Monitoring Board/Committee (DSMB/C)

An Independent Data Monitoring committee may be established by the Sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints and to recommend to

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

the Sponsor whether to continue, modify or stop a trial. The Sponsor shall include charter of work, membership and curriculum vitae of all the DSMB members when applicable. DSMB shall sign the charter and copy of updated CVs shall be submitted. It is recommended that at least one member of the DSMB is Rwandese.

2.2.9 Materials Transfer Agreement (MTA)

Where applicable, an appropriate MTA which defines the rights, obligations and restrictions for the provider (PI) and recipient(s) (External Laboratory) with respect to the materials and any derivatives to be Transferred, as well as any confidential information exchanged with the material shall be provided. The MTA shall specify:

- a) The type of materials to be transferred
- b) The local laboratory or institution from which the samples shall be transferred
- c) The destination of the samples (intermediary and final destination)
- d) The type of analyses to be carried out by the recipient(s)
- e) Competence of the recipient(s) of the materials for the listed analyses to be carried out

The MTA shall be duly signed and dated by the Sponsor, PI and the recipient(s) of the materials at external laboratory.

2.2.10 Investigational Product (IP) Dossier

The investigational product dossier (IPD) gives information related to the quality of any IP (i.e. including reference product and placebo), manufacture and control of the IP, and data from non-clinical studies and from its clinical use shall be provided according to the ICH CTD format. The applicant shall fill in the summary of the quality of the Investigational product in the Quality Overall Summary template as per **ANNEX-V** as well as additional Quality information as outlined in the template, should be completed as stipulated in the guidelines.

Any additional information that can support the chemistry, manufacturing and control (CMC) of the Investigational Product including but not limited to non-clinical studies, clinical studies and the relevant batch analysis results should be provided as attachments.

Non-clinical data shall be required together with the application package according to the latest version ICH M3 Non-clinical safety studies for the conduct of human clinical trials. Generally, in many cases where the IP has a marketing authorization, the investigational product dossier is not required and summary of product characteristics shall be sufficient. However, for placebo-controlled studies, a qualitative list of the ingredients in the placebo shall be submitted.

2.2.11 Evidence of Good Manufacturing Practices (GMP) compliance

To support the quality of the investigational product (s), the Authority shall rely and accept a valid GMP certificate or confirmation of GMP compliance or GMP inspection report issued by but not limited to:

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

- a) Stringent Regulatory Authorities/WHO listed authorities;
- b) Competent Authority of countries that are standing PIC/s members;
- c) World Health Organization (WHO) prequalification program;
- d) Authorities operating at least at maturity level 3(ML3)
- e) Competent Authority that has a recognition agreement with the Authority;
- f) EAC Joint GMP inspection procedure.

In case the investigational product is manufactured in a country whose GMP control system is not recognized by the Authority, but the clinical trial has been authorized by one of the above-stated bodies a, b, c, d, e, and f, the decision from that body may be considered.

3.0. Requirements for amendment of approved clinical Trial

3.1 Substantial amendments

The substantial amendment are major changes to the terms of the protocol or any other trial-supporting documentation that is likely to have significant impact and affect the safety and integrity of trial participants, the scientific value of the clinical trial, the conduct or management of the clinical trial, and the quality or safety of any investigational product. All substantial amendment require approval by the Authority.

Sponsors and investigators are required to file Clinical Trial Application Amendment (CTAA) for changes to the protocol and investigational product made after the original CTA that will impact on the safety of the trial participants or will affect the analysis and the interpretation of the safety and efficacy of the drug(s) under investigation. CTAA must be filed and approved by the Authority before such amendments are implemented when the proposed amendments to the protocol or investigational product (s):

- a) Affect the selection, assessment, or dismissal of a clinical trial participants;
- b) Affect the evaluation of the clinical efficacy of the investigational products;
- c) Alter the risk to the health of a clinical trial participants;
- d) Affect the safety evaluation of the investigational products or
- e) Extend the duration of the treatment.

If such amendments are necessary to protect the life of participants, an urgent amendment may be implemented but the investigator shall inform the ethics committee and the Authority of such amendments with immediate communication (e-mail) within 48 hours. An application for approval of the amendment, which clearly identifies the change and the rationale for immediate implementation of the change, shall be submitted within 15 days after the date of implementation of the amendment.

The substantial amendments submitted when the CTA is under review will not be accepted. He /she sponsor should withdraw the active CTA and submit the amendment as a new CTA. However, non-substantial amendments shall be notified and shall be handled as additional information to the application.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

3.1.1 Non-substantial amendments

The non-substantial amendments shall not require the approval of the Authority, but, shall be submitted as notification including the rationale of the change and supporting document must be submitted within 15 days of the implementation of the change. A line list of all notifications must be submitted along with the annual progress report.

The changes may be implemented and notify to the Authority. The recorded changes shall be availed to the Authority upon request during GCP inspection at the trial site. The examples of non-substantial amendment that require notification are provided as **ANNEX VII**

3.2 Filing a Clinical Trial Application Amendment

The CTAA shall be submitted to the Authority in the same way as a new CTA. The regulatory requirements shall differ depending on the type of amendment.

The sponsor or principal investigator shall submit the following documents:

- a) Signed and dated cover letter of Clinical Trial Application for amendment
- b) Copy of the Clinical Trial Approval Certificate
- c) Signed and dated clinical trial application form for an amendment
- d) Valid Ethical Clearance Certificate from Rwanda National Ethics Committee
- e) Copy of the most recently authorized protocol, including version number.
- f) Updated protocol highlighting the proposed amendments if applicable
- g) Copy of ICF with changes clearly highlighted if the amendment affects the ICF
- h) Addendum to the IB describing any new Quality information, if applicable
- i) Supporting data as required depending the amendment of quality of the investigational products (revised CMC information with track changes that have been submitted in the initial clinical trial application, and summary of changes on the CMC information) as applicable.
- j) Evidence of payment of prescribed fees.

The authority reserves the rights to request any other documents deemed necessary to support the safety of the trial participants.

Note: Each amendment related to an IP and that leads to a new potential risk for the trial participants must be considered as a substantial amendment.

3.3 Requirements for Renewal of Clinical Trial Authorization

In case the implementation period of the trial is more than one (1) year, the sponsor or principal investigator apply for renewal of Clinical Trial Authorization to continue the implementation of the trial one (1) month before the expiration of the certificate previously issued. The application shall consist of the following documents:

a) Signed and dated Clinical Trial Application letter for renewal;

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

- b) Copy of the Clinical Trial Approval Certificate to be renewed;
- c) Valid Ethical Clearance Certificate from Rwanda National Ethics Committee;
- d) Valid Local Insurance Policy Covering trial participants;
- e) Copy of protocol and its amendments (if applicable) that is being implemented;
- f) Updated investigational brochure if applicable;
- g) Updated progress report of the implementation of the trial according to the format provided in the guidelines on GCP in Rwanda.

In case of the extension of the trial implementation period, the applicant shall provide justification, all above-mentioned documents, and any other documentation deemed necessary by the Authority.

3.4 Application for import of Investigational Products

The sponsor or principal investigator shall be required to obtain an import permit for importation of Investigational products after authorization of the trial. A copy of the import authorization is required if the investigational product is not directly imported from the manufacturing country to the trial site.

The full requirements for importation and exportation of IP are detailed in guidelines for importation and exportation of Pharmaceutical products. In case of exportation of leftover for the Investigational Products after the completion of the trial, the sponsor or principal investigator shall obtain export permit or destruction certificate from the Authority.

3.5 Requirements for labelling and blinding of Investigational Products

The following information shall be labelled on the carton, inner label and the blisters or strips of the investigational drug product for a clinical trial:

Parameters	Unit carton	Inner Labels	Blister/Strips/
	or subject kit		Vials
Clinical Trial Protocol Number	\checkmark	$\sqrt{*}$	\checkmark
No, of Subjects or Initial of subject	$\sqrt{**}$	$\sqrt{**}$	$\sqrt{**}$
Investigational Drug Product name or code		\checkmark	
Dosage form		$\sqrt{*}$	$\sqrt{**}$
Name of Active substance	\checkmark	\checkmark	\checkmark
List of excipients	\checkmark	$\sqrt{*}$	$\sqrt{*}$
Strength	\checkmark	\checkmark	\checkmark
Instructions for use	$\sqrt{**}$	$\sqrt{**}$	$\sqrt{**}$
Lot number	$\sqrt{**}$	\checkmark	
Batch number	\checkmark	$\sqrt{**}$	$\sqrt{**}$
Manufacturing date	\checkmark	$\sqrt{**}$	
Expiry date		\checkmark	

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

For clinical Trial use only/Cautionary	\checkmark	$\sqrt{*}$	\checkmark
statement			
Name and address of Manufacturer	$\sqrt{***}$	$\sqrt{***}$	$\sqrt{***}$
Route of administration	\checkmark		\checkmark
Storage condition	\checkmark	\checkmark	\checkmark
Pack size (Unit/Vol)	\checkmark		\checkmark

NA Not Applicable

* Exempted for small label such as ampoule and vial.


** Where applicable

*** With letter of authorization where it applies

If the product is supplied without an outer carton, the information that is required on the outer carton should be stated on the inner carton. In blinded trials, the coding system for the investigational product(s) should include a mechanism that permits rapid identification of the product(s) in case of a medical emergency, but does not permit undetectable breaks of the blinding.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023





Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

APPENDIX II: Phases of Clinical Trials

Phase I

These are the first trials of a new active ingredient or new formulations in man, often carried out in healthy volunteers. Their purpose is to establish a preliminary evaluation of safety, and a first outline of the pharmacokinetic and, where possible, a pharmacodynamic profile of the active ingredient in humans. These trials are tested in a small group of people between 20 to 100 health volunteers.

Phase II

These trials are performed in a limited number of subjects and are often, at a later stage, of a comparative (e.g. placebo-controlled) design. Their purpose is to demonstrate therapeutic activity and to assess short-term safety of the active ingredient in patients suffering from a disease or condition for which the active ingredient is intended. This phase also aims at the determination of appropriate dose ranges or regimens and (if possible) clarification of dose response relationships in order to provide an optimal background for the design of extensive therapeutic trials. These trials are tested in a larger group of people generally 100–300 participants with a specific disease.

Phase III

Trials in larger (and possibly varied) patient groups with the purpose of determining the short and longterm safety/efficacy balance of formulation(s) of the active ingredient, and of assessing its overall and relative therapeutic value. The pattern and profile of any frequent adverse reactions must be investigated and special features of the product must be explored (e.g. clinically-relevant drug interactions, factors leading to differences in effect such as age). These trials should preferably be of a randomized double-blind design, but other designs may be acceptable, e.g. long-term safety studies. Generally, the conditions under which these trials are carried out should be as close as possible to normal conditions of use generally in 300 to 3,000 volunteers who have the disease or condition.

Phase IV

Studies performed after marketing of the pharmaceutical product. Trials in phase IV are carried out on the basis of the product characteristics on which the marketing authorization was granted and are normally in the form of post-marketing surveillance, or assessment of therapeutic value or treatment strategies. Although methods may differ, these studies should use the same scientific and ethical standards as applied in premarketing studies. After a product has been placed on the market, clinical trials designed to explore new indications, new methods of administration or new combinations, etc. are normally considered as trials for new pharmaceutical products.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

APPENDIX III: List of possible amendments to an approved trial

CHAN	NGES RELATED TO CLINI	CAL PROTOCOL		
#		e but are not limited to the fo	llowing:	Туре
1	Criteria, tests or procedures required to select or dismiss a clinical trial participant. These include changes to eligibility criteria, tests or procedures for selecting the study population, as well as tests, procedures, or criteria for dismissing clinical trial participants prematurely or at the end of the trial;			Amendment
2	trial participants, including a	required for the ongoing asses assessment of safety, or evaluation of control of set o	tion of safety and	Amendment
3	including adding or discont provision in the original CT.	*	not included as a	Amendment
4	endpoints (e.g., those that application), safety endpoint	icacy endpoint(s), important set t could be used in support ts, sample size estimation, or ac analysis and interpretation of th	of a marketing ddition of interim	Amendment
5	Dose level, dosage schedule	, or treatment duration;		Amendment
6	Changes to the post-treatment follow-up period that may affect the safety evaluation of the drug.			Amendment
7	Adding or removing a concomitant medication, which may impact on the analysis of efficacy or increase the risk to clinical trial participants;			Amendment
8	Criteria for expedited reporting of serious, unexpected adverse drug reactions;			Amendment
9	Increases in blood volume, changes in procedures, enrolling additional subjects in PK studies or confirmatory testing in PK studies that were not specified in the original CTA protocol; and/or			Amendment
10	Aspects of the conduct of the study that may increase the risk to the health of clinical trial participants.			Amendment
11	Increasing the screening period or other administrative changes to accommodate logistical constraints in study conduct that do not affect the safety of the trial participants			Notification
12	0	sion and exclusion criteria, su t reflect clinical practice and ir	•	Notification
13	Changes to administrative information such as new contact names and numbers and ages of individuals, organizations, or other entities, involved in the conduct of the trial;			Notification
14	Updating the ICF with new safety information that does not require a protocol amendment;		Notification	
15	Annual Investigator Brochure updates		Notification	
16	Changes to the quality info of the investigational produc	rmation that does not affect the	quality or safety	Notification
(UALITY (CMC) OF INVES	FIGATIONAL P	RODUCT
Doc. No.: FDISM/PVSM/GDL/005 Revision Date: 01/04/2023 Review Due Date: 10/04/2026				
Revision No.: 02Approval date: 05/04/2023Effective Date: 11/04/2023			1/04/2023	

		logics and Radiopharmaceutio			
#	Example of changes include but are not limited to the following:				
1		a manufacturing site involving:			
		material, intermediate, or drug	substance	Amendment	
	b. testing (e.g., release, stabi			Notification	
2		g process for the drug substance			
	technology, use of new raw route of synthesis of the	<pre>s [for example (e.g.), scale-up materials of biological origin]; bstance or critical component*</pre>		Amendment	
		ess (e.g., addition/removal/rep	placement of a	Amendment	
3		for the drug substance involvin			
	a. deletion or replacement of addition of a test for a new i	of a test, relaxation of an accept mpurity	tance criterion or	Amendment	
	b. addition of a test (other the of an acceptance criterion	an a test for new impurity) or ti	ghtening	Notification	
4	shipment of the drug subs system is at least equivalen	ntainer closure system(s) for tance provided the proposed of t to the approved container clo erties, and the change does not	container closure sure system with	Notification	
5		he drug substance, involving:			
-	a) Extension			Amendment	
	,	fe is less than or equal to 18 mo	nths	Amendment	
		fe is more than 18 months	intitis	Notification	
	b) Reduction (due to stab			Amendment	
	, , , , , , , , , , , , , , , , , , , ,	JCT (Biologics and Radiophar	maceuticals)		
#	Type of Change			Туре	
1		a dava anodu at monufo atuaina ai	to involving.	Type	
1		a drug product manufacturing si			
	a. production of a drug prod	uct (including primary packagin	ng)		
	b. secondary packaging				
	c. testing [for example (e.g.)	release, stability]			
2	Change in the drug product the formulation process); ch	manufacturing process (e.g., sca ange from manual synthesis of	positron-emitting	Amendment	
3	 radiopharmaceutical to use of automatic synthesis unit or change in type. Deletion of a drug product manufacturer / manufacturing site, primary or secondary packaging site or testing site 			Notification	
4	* * * * *	for the drug product, involving	:		
	or addition of a test for a new			Amendment	
	acceptance criterion	than a test for new impurity) or	r tightening of an	Notification	
5	Change in the shelf life for t	he drug product, involving:			
oc. N	o.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date	: 10/04/2026	
evisio	on No.: 02	Approval date: 05/04/2023	Effective Date: 1	1/04/2023	

	a. Extension			Amendment
		fe is less than or equal to 18 mo	nths	
		elf life is more than 18 months		Notification
	b. Reduction (due to stabi			Amendment
6	Change in the storage condit			Amendment
7	formulation)	sage form (e.g., liquid to lyophi	lized	Amendment
8	Changes in final product stre	ength		Amendment
9	lyophilized powder or co commercially available in solution, and after reconsti- specifications outside of the		luent, which is (WFI) or a salt	Notification
10.	Change in radiolytic protect			Amendment
	DRUG	SUBSTANCE (Pharmaceutic	als)	
#	Type of Change:			Туре
1	Replacement or addition of a	a manufacturing site involving:		
	a. production of drug substat	nce		Amendment
	b. testing (e.g., release, stabi	lity)		Notification
2	Change in the manufacturing process for the drug substance intermediate or starting material (e.g., reaction conditions, solvents, catalysts, synthetic routes, reagents, etc.)		Amendment	
3		the drug substance (no impact on quality)		Notification
4	Change in the specification	for the drug substance involv	ing test and accep	otance criteria
	addition of a test for a new i	f a test, relaxation of an accepta mpurity		Amendment
	b. addition of a test (other th acceptance criterion	an a test for a new impurity) or		Notification
5	<u> </u>	(or shelf life) for the drug substa	ance, involving:	
	a. Extension			Notification
	b. Reduction (due to stability	y concerns)		Amendment
	D	RUG PRODUCT (Pharmaceu	iticals)	
1	Addition of a dosage form o	r strength		Amendment
2	Change in the composition of a dosage form		Amendment	
3	Qualitative or quantitative addition, deletion or replacement of a colour or flavour with no negative impact on stability		Notification	
4			Amendment	
5	Replacement or addition of site involving:	a drug product manufacturer /	manufacturing	
Doc. N	o.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date	: 10/04/2026
Revisio	on No.: 02	Approval date: 05/04/2023	Effective Date: 1	1/04/2023

	a. Production of an immediate release drug product (tablet, capsule, liquids, semi-solids) within the same Manufacturer	Notification
	b. Production of an immediate release drug product (tablet, capsule, liquids, semi-solids) to a new Manufacturer	Amendment
	c. Production of a modified release product	Amendment
	d. Production of a sterile drug product	Amendment
	e. Primary packaging (non-sterile products)	Notification
	f. Testing (e.g., release, stability)	Notification
6	Change in the drug product manufacturing process	Amendment
7	Change in the specification for the drug product tests and acceptance criteria, involving:	
	a. Deletion or replacement of a test, relaxation of an acceptance criterion, or addition of a test for a new impurity	Amendment
	b. addition of a test (other than a test for a new impurity) or tightening of an acceptance criterion	Notification
8	Change in the shelf life for the drug product, involving:	
	a. Extension	Notification
	b. Reduction (due to stability concerns)	Amendment
9	Change in the storage conditions for the drug product	Amendment

ENDORSEMENT OF THE GUIDELINES

	Author	Authorized by	Checked by	Approved by
	Division Manager	Head of Food &	Quality Assurance	
Title	of	Drugs Inspections	Analyst	Director General
	Pharmacovigilance	& Safety		
	& Food Safety	Monitoring		
	Monitoring	Department		
Names	NTIRENGANYA	Dr. Eric	NDAYAMBAJE	Dr Emile
	Lazare	NYIRIMIGABO	Théogène	BIENVENU
Signature				
	(weine)	Muth	Arbywer	
Date	04/04/2023	04/04/2023	05/04/2023	06 / 04 / 2023

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-I: Clinical Trial Application Form (CTA)

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 2022			Department/Division /Office/Unit	FDISM/PVSM/CT	
Document Type: For	n			Doc. No	: FDISM/PVSM/FOM/xxx
Title: Clinical		al Trial Application	Revision Number	: 01	
				Revision Date:	: 28/02/2023
			Effective Date	: 28/02/2023	
RWANDA FDA Rwanda Food and Drugs Authority			Review Due Date	: 28/02/2023	
				Ref Doc.	: FDISM/PVSM/GDL/005

Clin	ical Trial Application Form (CTA)	Routine CTA Non-Routine CTA
1.	Title of the Study:	
2.	Protocol Number :	
3.	Protocol version number	
4.	Protocol date:	
5.	Clinical trial Phase	
6.	Trial objectives	
7.	Trial Design:	
8.	Investigational product's name, number or identifying mark	
9.	Indications	
10. 11.	Comparator product (if applicable Concomitant medications (if applicable	
12.	Number of Participants	
13.	Trial Site (s)	
14.	Duration of the trial	
15.	Amount paid for this application	
16.	Sponsor's names	Names: Institution: E-mail address: Phone number (with country code):
17.	Principal Investigator's names	Names: Institution E-mail address: Phone number (with country code):
18.	Contact Person names and Full address	Names: Institution E-mail address:
[Doc. No.: FDISM/PVSM/GDL/005 Revis	ion Date: 01/04/2023 Review Due Date: 10/04/2026

Approval date: 05/04/2023

Effective Date: 11/04/2023

Revision No.: 02

		Phone	e number (with country code):	
DEC	CLARATION BY THE APPI	LICANT		
19.	 I, (<i>Insert the names of Sponsor or PI</i>) the undersigned, hereby declare that I have submitted all required documentations, and have disclosed all information which may influence the approval of this application I, hereby declare that all information contained or referenced in this application is complete, accurate and is not false or misleading. I, agree and ensure that once the above said clinical trial is approved, will be conducted according to the submitted protocol, legal, ethical and regulatory requirements of Rwanda FDA 			
20.	Names of applicant	Signature	Date	

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX- II: Clinical Trial Protocol Format

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 2	022	Department/Division /Office/Unit	FDISM/PVSM/C7	Γ
Document Type: For	n		Doc. No	: FDISM/PVSM/FOM/xxx
	Title: Clinic	al Trial Protocol	Revision Number	: 01
	Format		Revision Date:	: 28/02/2023
Charles			Effective Date	: 28/02/2023
RWANDA FDA Rwanda Food and Drugs Authority			Review Due Date	: 28/02/2023
			Ref Doc.	:FDISM/PVSM/GDL/xxx

This template should be filled in and submitted in Microsoft word fo size 12 black ink)	rmat with times new roman style font
GENERAL INFORMATION	
Title of Study	
Protocol Identification Number/code	
Protocol Version Number (where applicable)	
Date of Protocol	
Rwanda FDA Application Number	
Ethical Clearance Number/ Date of Approval	
Name of Investigational Product or Intervention	
Therapeutic Classification	
Dosage Form(s) and Strength(s)	
Route(s) of Administration	
Name of Comparator Product (where applicable)	
Name and address(es) of the Applicant	
Name and address(es) of the Sponsor	
Name and address(es) of the Principal Investigator (PI)	
Name and address(es) of the Study Monitor	
Name and address(es) of Study Site(s)	
Name and address of the manufacturer of investigational product	

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

Name and address of the manufacturer of comparator product (if					
applicable)					
Phase of Trial					
Duration of study					
1 BACKGROUND AND RATIONALE					

(Insert a brief, concise introduction into the clinical problem and previous treatments and developments, i.e., pertinent data from previous preclinical/clinical pharmacology studies and therapeutic exploratory studies taking into account relevant scientific literature (citations by consecutive numbering, with list at end of this section; important or not readily available references may be included with the paper submission, if appropriate). This section should also contain information on the new drug). Provide rationale for conducting the study in Rwanda

2. OBJECTIVE OF THE TRIAL

(Insert the objectives that are the same as the objectives contained in the protocol. Include the primary objective and secondary objectives)

Primary Objective(s):

Secondary Objective(s):

3. STUDY ENDPOINTS

(Insert the endpoints that are the same as the endpoints contained in the body of the protocol. Include the primary endpoint and important secondary endpoints)

Primary Endpoint(s):

Secondary Endpoint(s):

4. STUDY DESIGN

^{4.1} Insert summary description of the type/design of trial to be conducted (e.g. double-blind, placebocontrolled, parallel design). Provide a simple summarized snapshot of your study design not to exceed a single page. This section should include a diagram that provides a quick to 1 page. Please present an overview of your study design in a schematic diagram and tables. The data presentation can be adapted depending on the nature of your study and can be customized according to your protocol. Example: complete the tables with study-specific information and adapt the table(s) to illustrate your study design.

Arm 1	Sample size		Intervention A	
Doc. No.: FDISM/PVSM/GDL/005		Rev	ision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02		App	proval date: 05/04/2023	Effective Date: 11/04/2023

 ^{4.3} Blinding (methods of blinding (masking) and other bias reducing techniques to be used); ^{4.4} Summary description of the trial treatment(s) and the dosage and dosage regimen of the nvestigational product(s), including packaging, and labeling of the investigational product(s); ^{4.5} Maintenance of trial treatment randomization codes and procedures for breaking codes; ^{4.6} Total study duration (anticipated starting/finishing dates); ^{4.7} Expected duration for each subject including post treatment period etc; ^{5.1} Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification ^{5.2} Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stag 	Arm 2	Sample size	Intervention B	
 boints, interventions etc. 4.2 Summary of the randomization method and procedures to allocate participants to treatment groups; 4.3 Blinding (methods of blinding (masking) and other bias reducing techniques to be used); 4.4 Summary description of the trial treatment(s) and the dosage and dosage regimen of the nvestigational product(s), including packaging, and labeling of the investigational product(s); 4.5 Maintenance of trial treatment randomization codes and procedures for breaking codes; 4.6 Total study duration (anticipated starting/ finishing dates); 4.7 Expected duration for each subject including post treatment period etc; 5. STUDY PARTICIPANTS 5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stag 	nclude instructio	ns for progressing to next p	phase (if applicable):	
 5. STUDY PARTICIPANTS 5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, and 			esign, procedures and sta	ages including study arms, visits, time-
 4.4 Summary description of the trial treatment(s) and the dosage and dosage regimen of the investigational product(s), including packaging, and labeling of the investigational product(s); 4.5 Maintenance of trial treatment randomization codes and procedures for breaking codes; 4.6 Total study duration (anticipated starting/finishing dates); 4.7 Expected duration for each subject including post treatment period etc; 5. STUDY PARTICIPANTS 5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stage) 	1.2 Summary of t	he randomization method o	and procedures to allocate	e participants to treatment groups;
 a. 5 Maintenance of trial treatment randomization codes and procedures for breaking codes; a. 6 Total study duration (anticipated starting/ finishing dates); a. 7 Expected duration for each subject including post treatment period etc; 5. STUDY PARTICIPANTS 5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stage) 	4.3 Blinding (me	thods of blinding (masking) and other bias reducing	techniques to be used);
 4.6 Total study duration (anticipated starting/ finishing dates); 4.7 Expected duration for each subject including post treatment period etc; 5. STUDY PARTICIPANTS 5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stage) 	-		_	
 4.7 Expected duration for each subject including post treatment period etc; 5. STUDY PARTICIPANTS 5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stage) 	4.5 Maintenance	of trial treatment randomi	zation codes and procedur	res for breaking codes;
 5. STUDY PARTICIPANTS 5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stage) 	4.6 <i>Total study d</i>	uration (anticipated startin	ng/finishing dates);	
5.1 Participants' characteristics, Age ranges of participants, Gender, use of vulnerable participants, an ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stag	4.7 Expected dur	ation for each subject incli	uding post treatment perio	d etc;
ustification 5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stag	5. STUDY PAI	RTICIPANTS		
5.2 Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stag	5.1 Participants'	characteristics, Age rang	es of participants, Gende	er, use of vulnerable participants, and
	ustification			
ndication/ conditions/ treatment etc.) as applicable and of diagnostic criteria and assessment	5.2 Provide a b	rief description of specifi	c characteristics of the t	trial participants (e.g. disease/ stage/
	ndication/ condit	ions/ treatment etc.) as app	licable and of diagnostic o	criteria and assessment
		• • • •		

5.3 State the Inclusion criteria:

5.4 State the Exclusion criteria

6. PREMATURE WITHDRAWAL / DISCONTINUATION CRITERIA

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

6.1 *Withdrawal criteria:*

6.1.1 Enumeration of all conditions / criteria and management for drug/ patient's withdrawal or (premature) discontinuation, including voluntary withdrawal by subject without prejudice to future treatment by the physician. The type and timing of the data to be collected for withdrawn participants.

6.1.2 State whether and how participants are to be replaced.

6.1.3 The follow-up for participants withdrawn from investigational product treatment/trial

6.1.4 *Treatment*

6.2 State the stopping rules" or "discontinuation criteria" for individual participants, parts of trial and entire trial;

7. INVESTIGATIONAL DRUG FORMULATION

^{7.1} (Brief description of the study drug(s) and formulation to be used in the clinical trial. The relationship to the formulations used in the preclinical and/or other clinical trials should be delineated, as applicable. This may also include disclosure of the formulation intended to be marketed and/or any bridging studies which may be necessary, planned, initiated and/or already performed if different formulations have been used during clinical development.)

7.2 Instructions for safe handling;

^{7.3} State the accountability procedures for the investigational product(s), placebos and comparator(s) and disposal;

8. DOSAGE REGIMEN

8.1 Rationale for dose selection

8.2 *Provide the following regarding the treatment(s) to be administered:*

8.2.1 *The name(s) of all the product(s):*

8.2.2 *Dose(s)*:

8.2.3 The dosing schedule(s):

8.2.4 *The route/mode(s) of administration:*

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

8.2.5 *The treatment period(s):*

8.2.6 Follow-up period(s) for participants for each investigational product treatment/trial treatment group/arm of the trial:

8.2.7 *Concomitant Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before and/or during the trial:*

8.2.8 *Procedures for monitoring participant's compliance:*

8.2.9 *Wash-out period (Description for pre-, during- and post-trial, as applicable)*

9. PRE-STUDY SCREENING AND BASELINE EVALUATION

(Describe in summary the process of clinical validation for participation in the clinical trial, including methodology/schedule of events.)

10. TREATMENT / ASSESSMENT VISITS

(Insert the schedule of all events / visits / procedures during the clinical trial)

11. EFFICACY VARIABLES AND ANALYSIS

^{11.1}Description and validation of primary endpoint(s), i.e. responses/changes from baseline over time in relation to clinical trial events. Description and validation of related secondary changes (secondary endpoints) following from clinical trial events.

11.2 Provide specification of the efficacy parameters.

11.3 Describe the methods and timing for assessing, recording, and analyzing efficacy parameters

12. ASSESSMENT OF SAFETY

12.1 Specification of safety parameters:

12.2 The methods and timing for assessing, recording, and analyzing safety parameters:

12.3 Procedures for eliciting reports of and for recording and reporting adverse events and intercurrent illnesses.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

12.4 The type and duration of the follow-up of subjects after adverse events

^{12.5}*RISKS:* (Identify potential risks and mitigation strategies (e.g. need for and risks associated with long term immunosuppression)

12.6 DATA and SAFETY MONITORING PLAN (DSMP):

(Summarize the Data and Safety Monitoring Plan. Describe measures that will be implemented to minimize risk to study subjects e.g. specific inclusions/exclusions; plans to ensure medical intervention in the case of an adverse event for subjects; plans for surveillance, detection and management of specific adverse events that might or could occur; potential use of an Independent Safety Monitor or Data Safety Monitoring Board (DSMB)

^{12.7} *Immune Monitoring and immunosuppression: (Describe and justify the plan for immunosuppression and immune monitoring (if applicable)*

13. ASSAYS/METHODOLOGIES

^{13.1}Briefly describe any specialized assays or methodologies that will be used in this clinical study or supporting study/studies (Provide a more detailed summary of assay methods and summarize assay qualification/validation. Indicate where specialized testing will be conducted)

13.2 The names and contact addresses of the laboratories to be used for the study;

13.3 State the location of the attached draft Material Transfer Agreements (MTAs) in the submission;

13.4 State the duration for long term storage of samples and the area to be stored

14. STATISTICAL ANALYSIS PLAN

14.1 Specify the planned sample size to be used in the study and its justification

^{14.2} Summary of description of the statistical methodologies to be used to evaluate the effectiveness of the investigational product, including the hypotheses to be tested, the parameters to be estimated, the assumptions to be made and the level of significance and the statistical model to be used.

14.3 Analysis of trial parameters (primary/ secondary endpoints), population, demographics, as applicable.

14.4 *Efficacy analysis methods and results of efficacy end-point analysis.*

14.5 Safety analysis methods and results of safety end-point analysis.

14.6 *Exploratory end-point analysis: evaluation effect(s) (or lack of effects) of relevant biochemical/ pharmacological etc parameters, as applicable.*

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

- 14.7 *Pharmacokinetic endpoint analysis, as applicable.*
- 14.8 Interim analysis and role of Data Safety Monitoring Board, as applicable

15. OUTCOME CRITERIA

(Describe criteria that would define whether you would or would not move forward with the subsequent

development plan, based upon primary and designated secondary objectives)

16. DATA MANAGEMENT

(Describe procedures for recording, processing, handling, and retaining raw data and other study *documentation*)

17. MONITORING PLAN

(Summary of the monitoring plan)

State the location of the detailed monitoring plan in the submission

18. ETHICAL CONSIDERATIONS

18.1 State the ethical clearance reference number and institutions that have approved the trial

Institution review Board ethical clearance: Number and date

RNEC ethical clearance number and Date:

18.2 Insurance Details:

18.2.1 Insert local Insurance Company name and address:

18.2.2*policy cover number:*

18.2.3Validity:

18.2.4*Expiry Date:*

18.2.5 State the location of the Insurance cover in the submission:

18.2.6 Number of insured participants

18.3 Participant Information sheets and Informed Consent forms:

(The contents should be as per ICH guidelines, these guidelines and declaration of Helsinki)

18.3.1State the version number and dates for both English and Kinyarwanda

18.3.2State the location of the Participant Information sheets and Informed Consent forms in the submission

18.4 *State the amount to be reimbursed to the participants*

18.5 Treatment and/or management of participants and their disease condition(s) after completion of trial

18.6 Follow-up of trial study participants after the conclusion of the trial

18.7 In case of transfer of materials, provide Material Transfer Agreement (MTA) highlighting among other things, the following:

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

18.8 *Identification of the provider and recipient*

18.9 *Identification of the material and the volume of material*

18.10 Definition of the trial and how the material will and will not be used.

18.11 Maintenance of confidentiality of background or supporting data or information, if any

18.12 Indemnification and warranties (where applicable)

18.13 Details on post-trial access to the products

19. BENEFIT/RISK ASSESSMENT

Evaluation of the anticipated benefits and risks of participating in the trial and proposed measures to address

the known and potential risks of participating in the trial and to protect participants

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-III: Joint Declaration for Sufficient Funds

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 2	022	Department/Division/Office/Unit	Pharmacovigilance Division	and Food Safety Monitoring
Document Type: Form	n		Doc. No	: FDISM/PVSM/FOM/xxx
			Revision Number	: 01
	Title: Joint Declaration for Sufficient Funds Revision Date:	Revision Date:	: 28/02/2023	
		runus	Effective Date	: 28/02/2023
RWANDA FDA			Review Due Date	: 28/02/2023
Rwanda Food and Drugs Authority			Ref Doc.	: FDISM/PVSM/GDL/005

The Joint Declaration for Suffic	cient Funds should be completed and signed by Sponsor and National Principal			
Investigator concerning to Complete Study)				
Title of the study:				
Protocol:				
Investigational Product(s):				
I, <i><insert full="" name=""></insert></i> , Sponsor /representing the sponsor (<i>delete whichever is not applicable</i>) and I, <i><</i> full name>, Principal Investigator/National Principal Investigator hereby declare that sufficient funds have been made available to complete the above-mentioned study according to legal, ethical, and regulatory requirements currently enforced in Rwanda. Done at				
SPONSOR National /Principal Investigator:				
Name: Address: E-mail address: Phone number: Signed:	Name: Address: E-mail address: Phone number: Signed:			

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-IV: Declaration by principal investigator or co-investigator

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 20)22	Department/Division/Office/Unit	Pharmacovigilar Monitoring Divi	nce and Food Safety sion
Document Type: Forn	1		Doc. No	: FDISM/PVSM/FOM/xxx
		tle: Declaration by principal	Revision Number	: 01
	in	vestigator or co-investigator	Revision Date:	: 28/02/2023
Charles -			Effective Date	: 28/02/2023
RWANDA FDA Rwanda Food and Drugs Authority			Review Due Dat	te : 28/02/2023
			Ref Doc.	: FDISM/PVSM/GDL/005

Note that all investigators should fill and sign this form			
Title of clinical trial:			
Role in clinical trial:			
Title of clinical trial:			
Clinical trial protocol number:			
Investigational Product:			
Clinical trial site:			
DECLARATION			

I, (*Insert Full names*), the **principal investigator or co-investigator** (*delete as applicable*) in above mentioned study, hereby DECLARE that:

- 1. I am familiar with the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) and understand the responsibilities and obligations of the Principle Investigator (PI) within the context of this study.
- 2. I have notified the Rwanda FDA of any aspects of the study with which I do not/am unable to, comply. (If applicable, this may be attached to this declaration.)
- 3. I have thoroughly read, understood, and critically analyzed the protocol and all applicable accompanying documentation, including the investigator's brochure, patient information leaflet(s) and informed consent form(s).
- 4. I will conduct the trial as specified in the protocol and in accordance with Rwanda FDA requirements and ICH GCP principles.
- 5. To the best of my knowledge, I have the potential at the site(s) I am responsible for, to recruit the required number of suitable participants within the stipulated time.
- 6. I will not commence the trial before written authorization from the National Ethics Committee and Rwanda FDA has been obtained.
- 7. I will obtain informed consent from all participants or if they are not legally competent, from their legal

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

representatives.

- 8. I will ensure that every participant (or other involved persons), shall at all times be treated in a dignified manner and with respect.
- 9. Using the broad definition of conflict of interest below, I declare that I have no financial or personal relationship(s) which may inappropriately influence me in carrying out this clinical trial. [*Conflict of interest exists when an investigator (or the investigator's institution), has financial or personal associations with other persons or organizations that may inappropriately influence (bias) his or her actions*].
- 10. I have*/have not (delete as applicable) previously been the principal investigator at a site which has been closed due to failure to comply with ICH-GCP (*Attach details).
- 11. I have*/have not (*delete as applicable*) previously been involved in a trial which has been closed as a result of unethical practices. (*Attach details).

Principal Investigator:	Date	Signature

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-V: Investigational Product Quality Overall Summary Template

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 2	022	Department/Division/Office/Unit	t Pharmacovigilar Monitoring Divi	•
Document Type: For	n		Doc. No	: FDISM/PVSM/FOM/xxx
Inve		vestigational Product Quality Overall	Revision Number	: 01
	Summary Template Revision Date:	Revision Date:	: 28/02/2023	
Charles -			Effective Date	: 28/02/2023
RWANDA FDA Rwanda Food and Drugs Authority			Review Due Dat	te : 28/02/2023
			Ref Doc.	: FDISM/PVSM/GDL/005

This template should be filled in and submitted in Microsoft word format with New times roman style font size 1	2
black ink). Details on this summary should as inserted as prescribed in the CTD module 3.)	
Title of Study	
Protocol Identification Number/code	
Protocol Version Number (where applicable)	
Date of Protocol	
Rwanda FDA Application Number	
Name of Investigational Product or Intervention	
Therapeutic Classification	
Dosage Form(s) and Strength(s)	
Route(s) of Administration	
Clinical trial Design (<i>extract from the protocol</i>)	
Name of Comparator Product (where applicable)	
Name and address(es) of the Applicant	
Name and address(es) of the Sponsor	
Name and address(es) of the Principal Investigator (PI)	
Name and address(es) of the Study Monitor	
Name and address(es) of Study Site(s)	
Name and address of the manufacturer of	
investigational product	
Name and address of the manufacturer of comparator	
product (if applicable)	
Phase of Trial	
Proprietary (Brand) Name of FPP	
Non-proprietary or Common Name of Drug Substance	
(Medicinal Ingredient)	
Doc. No.: FDISM/PVSM/GDL/005Revision Date: 01/04/2023Review Due Date: 10/04/2026	
Revision No.: 02Approval date: 05/04/2023Effective Date: 11/04/2023	

Company Name	
Dosage Form(s)	
Strength(s)	
Country from which the Clinical Supplies were	
Obtained for the Lot to be Used in this Clinical Trial (as	
well as the market status in that country)	

2.3. S ACTIVE PHARMACEUTICAL INGREDIENT (NAME, MANUFACTURER)

2.3. S.1 General Information (name, manufacturer)

- 2.3. S.1.1 Nomenclature (name, manufacturer)
- (a) Recommended International Non-proprietary name (INN):
- (b) Compendial name, if relevant:
- (c) Chemical name(s):
- (d) Company or laboratory code:
- (e) Other non-proprietary name(s) (e.g., national name, USAN, BAN):
- (f) Chemical Abstracts Service (CAS) registry number:

Note: For Phase I Trials only (a) and (b) is required

2.3. S.1.2 Structure (name, manufacturer)

- (a) Structural formula, including relative and absolute stereochemistry:
- (b) Molecular formula:
- (c) Molecular mass:

2.3. S.1.3 General Properties (name, manufacturer)

- (a) Physical description (e.g., appearance, colour, physical state):
- (b) Physical form (e.g., preferred polymorphic form, solvate, hydrate):
- (c) Solubilities (e.g., aqueous/non-aqueous solubility profile, tabular format, reporting in mg/mL):
- (d) pH and pKa values:
- (e) Other relevant information:

2.3. S.2 Manufacture (name, manufacturer)

2.3. S.2.1 Manufacturer(s) (name, manufacturer)

(a) Name, address, and responsibility of each manufacturer, including

Contractors, and each proposed production site or facility involved in the manufacturing of the batches to be used in this clinical trial:

(b) List of referenced Drug Master Files (DMFs) and DMF Numbers (copies of

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

DMF letters of access should be located in Module 1):

2.3. S.2.2 Description of Manufacturing Process and Process Controls (name, Manufacturer)

(a) Flow diagram of the synthetic process(es):

Note: For Phase II & III include also the following should be submitted: -

(b) Detailed narrative description of the manufacturing process(es):

2.3.S.2.3 Control of Materials (name, manufacturer)

(a) For Active Pharmaceutical Ingredient manufactured with reagents obtained from sources that are at risk of transmitting Bovine Spongiform Encephalopathy (BSE)/Transmissible Spongiform Encephalopathy (TSE) agents (e.g., ruminant origin), provide an attestation (with supporting documentation, if applicable) confirming that the material is free of BSE/TSE agents:

Note: For Phase II & III include also the following should be submitted:

(b) Information on starting materials

2.3. S.2.4 Controls of Critical Steps and Intermediates (name, manufacturer)

- (a) Summary of the controls performed at critical steps of the manufacturing
- (b) Process and on intermediates:

2.3. S.3 Characterization (name, manufacturer)

2.3. S.3.1 Elucidation of Structure and other Characteristics (name, manufacturer)

(a) List of studies performed (e.g., IR, UV, NMR, MS, elemental analysis) and Summary of the interpretation of evidence of structure:

(b) Discussion on the potential for isomerism and identification of

Stereochemistry (e.g., geometric isomerism, number of chiral centres and configurations):

(c) Summary of studies performed to identify potential polymorphic forms (including solvates):

(d) Summary of studies performed to identify the particle size distribution of the

Active Pharmaceutical Ingredient:

(e) Other characteristics:

2.3. S.3.2 Impurities (name, manufacturer)

a. Identification of potential and actual impurities arising from the synthesis, manufacture and/or degradation:

b. List of drug-related impurities (e.g., starting materials, by-products, intermediates, chiral impurities, degradation products, metabolites), including chemical name, structure and origin:

	Drug-related Impurity	Structure	Origin
De	oc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Re	evision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Clinical Trial Applications in Rwanda

(chemical name or descriptor)	

(c) List of process-related impurities (e.g., residual solvents, reagents, catalysts), including compound name and step used in synthesis:

(d) Actual levels of impurities (e.g., drug-related and process-related) found in Batches used in nonclinical and clinical studies:

Impurity (drug-related and	Acceptance Criteria	Results (include batch number and use) (e.g., clinical)		e)
process-related)				

2.3. S.4 Control of the Active Pharmaceutical Ingredient (name, manufacturer)

2.3. S.4.1 Specification (name, manufacturer)

(a) Specification for the Active Pharmaceutical Ingredient:

Test	Acceptance Criteria	Analytical Procedure
		Analytical Procedure (Type and Source)

2.3. S.4.2 Analytical Procedures (name, manufacturer)

(a) Summary of the analytical procedures (e.g., suitability, key method parameters, conditions):

2.3. S.4.3 Validation of Analytical Procedures (name, manufacturer)

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Clinical Trial Applications in Rwanda

(a) Tabulated summary of the validation information (e.g., system suitability testing, validation parameters and results):

2.3. S.4.4 Batch Analyses (name, manufacturer)

(a) Description of the batches to be used in this clinical trial (or representative batches):

Batch Number	Batch Size	Date of Manufacture and Site of Production	Use (e.g., clinical)

(b) Summary of results for the batches to be used in this clinical trial or Representative batches (should include tests, types of analytical procedures (type and source), and actual results):

2.3. S.4.5 Justification of Specification (name, manufacturer)

(a) Justification of the Active Pharmaceutical Ingredient specification (e.g., manufacturing experience, stability, historical batch analysis results, safety considerations): *For Phase one trial only Batch analysis report is required.*

2.3. S.6 Container Closure System (name, manufacturer)

(a) Description of the container closure system(s) for the storage and shipment of the Active Pharmaceutical Ingredient:

2.3. S.7 Stability (name, manufacturer)

2.3. S.7.1 Stability Summary and Conclusions (name, manufacturer)

(a) Summary of stability studies to support this clinical trial (e.g., studies conducted, protocols used, results obtained):

(b) Proposed storage conditions and re-test period (or shelf life, as appropriate):

2.3. S.7.2 Stability Protocol and Stability Commitment (name, manufacturer)

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

(a) If full long term stability data is not available at the time of filing, provide a summary of the stability protocol and a commitment for the continued monitoring of the Active Pharmaceutical Ingredient stability according to the protocol:

2.3. S.7.3 Stability Data (name, manufacturer)

(a) The actual stability results (i.e., raw data) may be found in:

(b) Summary of analytical procedures and validation information for those

Procedures not previously summarized in 2.3.S.4 (e.g., analytical procedures used only for stability studies):

2.3. P FINISHED PHARMACEUTICAL PRODUCT (NAME, DOSAGE FORM)

2.3.P.1 Description and Composition of the FPP (name, dosage form)

(a) Description of the dosage form:

(b) Composition of the dosage form:

(i) Composition, i.e., list of all components of the dosage form, and their amounts on a per unit basis (including overages, if any):

Function	Strength (label	claim)		
	Quantity per unit	%	Quantity per unit	%
		Quantity	Quantity %	Quantity % Quantity

(i) Composition of all *components that are mixtures* (e.g., colorants,

coatings, capsule shells, imprinting inks):-

a) Description of reconstitution diluent(s), if applicable:

b) Type of container closure system used for accompanying reconstitution diluent, if applicable:

c) Qualitative list of the components of the placebo samples to be used in this

Clinical trial, if different from the components listed in 2.3. P.1(b):

2.3. P.2 Pharmaceutical Development (name, dosage form)

(a) Discussion on the development of the dosage form, the formulation,

Manufacturing process, etc.:

(b) For sterile, reconstituted products, summary of compatibility studies with Diluents/containers:

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

2.3. P.3 Manufacture (name, dosage form)

2.3. P.3.1 Manufacturer(s) (name, dosage form)

(a) Name, address, and responsibility of each manufacturer, including

contractors, and each proposed production site or facility involved in the manufacturing of the batches to be used in this clinical trial:

(b) List of referenced Drug Master Files (DMFs) and DMF Numbers (copies of

DMF letters of access should be located in Module 1):

(c) Attestation that the dosage form was manufactured under Good

Manufacturing Practices (GMP) conditions:

2.3. P.3.2 Batch Formula (name, dosage form)

(a) List of all components of the dosage form to be used in the manufacturing

process, and their amounts on a per batch basis (including overages, if any):

Strength (label claim)	
Batch Size(s) (number of dosage units)	
Component and Quality Standard (and	Quantity per batch
Grade, if applicable)	
Total	

2.3. P.3.3 Description of Manufacturing Process and Process Controls (name, dosage form)

(a) Flow diagram of the manufacturing process:

(b) Detailed narrative description of the manufacturing process, including

Equipment type and working capacity, process parameters (for Phase II & III trials)

(b) For sterile products, details and conditions of sterilization and lyophilization:

2.3. P.3.4 Controls of Critical Steps and Intermediates (name, dosage form)

(a) Summary of controls performed at the critical steps of the manufacturing Process and on isolated intermediates (*for Phase II & III trials*)

2.3. P.4 Control of Excipients (name, dosage form)

2.3. P.4.1 Specifications (name, dosage form)

Specifications for non-compendial excipients and for compendial excipients Which include supplementary tests not listed in the monograph(s) may be found in:

(a) List of referenced Drug Master Files (DMFs) and DMF Numbers (copies of

DMF letters of access should be located in Module 1):

2.3. P.4.5 Excipients of Human or Animal Origin (name, dosage form)

(a) List of excipients that are of human or animal origin (including country of origin):

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

(b) Summary of the information (e.g., sources, specifications, description of the

Testing performed, viral safety data) regarding adventitious agents for excipients of human or animal origin:

For excipients obtained from sources that are at risk of transmitting Bovine

Spongiform Encephalopathy (BSE)/Transmissible Spongiform Encephalopathy (TSE) agents (e.g., ruminant origin), provide an attestation (with supporting documentation, if applicable) confirming that the material is free of BSE/TSE agents:

2.3. P.4.6 Novel Excipients (name, dosage form)

(a) Summary of the details on the manufacture, characterization, and controls,

With cross references to supporting safety data (nonclinical and/or clinical) on novel excipients (i.e., those used for the first time in a FPP or by a new route of administration):

2.3. P.5 Control of FPP (name, dosage form)

2.3. P.5.1 Specification(s) (name, dosage form)

(a) Specification(s) for the FPP:

Test	Acceptance Criteria	Analytical Procedure
		(Type and Source)

2.3. P.5.2 Analytical Procedures (name, dosage form)

(a) Summary of the analytical procedures (e.g., key method parameters, conditions, suitability):

2.3. P.5.3 Validation of Analytical Procedures (name, dosage form)

(a) Tabulated summary of the validation information (e.g., system suitability testing, validation parameters and results):

2.3. P.5.4 Batch Analyses (name, dosage form)

(a) Description of the batches to be used in this clinical trial (or representative batches):

Strength and	Batch Size	Date	of	Input Drug	Use (e.g.,
Batch Number		Manufacture		Substance Batch	clinical)
		and Site	of		
		Production			

(b) Summary of results for the batches to be used in this clinical trial or

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

Representative batches (should include tests, types of analytical procedures (type and source), and actual results):

Note: For Phase one trial only Batch analysis report is required.

- 2.3. P.5.5 Characterization of Impurities (name, dosage form)
- (a) Information on the characterization of impurities, not previously provided in
- 2.3. S.3.2 (e.g., summary of actual and potential degradation products):
- 2.3. P.5.6 Justification of Specification(s) (name, dosage form)
- (a) Justification of the Active Pharmaceutical Ingredient specification (e.g., manufacturing
- experience, stability, historical batch analysis results, safety considerations):

2.3.P.7 Container Closure System (name, dosage form)

(a) Description of the container closure systems, including unit count or fill size, container size or volume:

- (b) Materials of construction of each primary packaging component:
- (c) For sterile products, details of washing, sterilization and depyrogenation
- d) Procedures for container closures:

2.3. P.8 Stability (name, dosage form)

- 2.3. P.8.1 Stability Summary and Conclusions (name, dosage form)
- (a) Summary of stability studies to support this clinical trial (e.g., studies conducted, protocols used, results obtained):
- (i) Description of stability study details:

Storage Conditions	Strength and	Batch Size	Container	Completed (and
(oC, % RH, light)	Batch Number	and Date of	Closure System	Proposed) Test
		Manufacture		Intervals

(ii) Summary and discussion of stability study results:

(b) Proposed storage conditions and shelf life (and in-use storage conditions and in-use period, if applicable):

2.3. P.8.2 Post-approval Stability Protocol and Stability Commitment (name, dosage form)

(a) If full long term stability data is not available at the time of filing, provide a summary of the stability protocol and a commitment that the stability of the clinical trial samples or representative batches will be monitored throughout the duration of the clinical trial or proposed shelf life:

2.3. P.8.3 Stability Data (name, dosage form)

(a) The actual stability results (i.e., raw data) may be found in:

(b) Summary of analytical procedures and validation information for those Procedures not previously summarized in 2.3.P.5 (e.g., analytical procedures used only for stability studies):

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

5. Additional Requirements for Clinical trials for medical devices

An application to authorize a clinical trial involving a medical devices or diagnostics shall be made in accordance with provisions provided in section 2 of these guidelines. In addition, the following documentation will be required;

- a) Device Description, design and materials including User manual, catalogue of IFU of the device.
- b) Marketing history
- c) Risk assessment and standard list
- d) Toxicology and biological safety
- e) Sterilization validation
- f) Electrical safety
- g) Safety and usefulness of medicinal substance
- h) Safety and appropriateness of use of tissues of animal origin
- i) Signed and approved protocol with data compiled as prescribed in ANNEX-II and current ISO standards.
- j) Certificate of ISO/ Quality audit (ISO 13485) for manufacturer of the device if applicable.

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-VI : Protocol Pre-Submission Synopsis

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 2022		Department/Division/Office/Unit	Pharmacovigilan Monitoring Divis	ce and Food Safety sion
Document Type: Form	n		Doc. No	: FDISM/PVSM/FOM/xxx
Title		Protocol Pre-Submission Synopsis	Revision Number	: 01
		Template Revision I	Revision Date:	: 28/02/2023
Caller			Effective Date	: 28/02/2023
RWANDA FDA Rwanda Food and Drugs Authority			Review Due Dat	e : 28/02/2023
			Ref Doc.	: FDISM/PVSM/GDL/005

	Protocol Pre-Submission Synopsis Template				
1.	Title of the Study:				
2.	Sponsor name:				
3.	Investigational Product (s)				
4.	Background and Rationale (Brief)				
5.	Indication (s)				
6.	Clinical trial Phase				
7.	Trial objectives	Primary objectives:			
		Secondary Objectives):			
8.	Trial Design				
9.	Trial End points	Primary endpoints:			
		Secondary endpoints:			
10.	Number of Participants				
11.	Eligibility criteria	Inclusion criteria:			
		Exclusion criteria:			
12.	Trial Site (s)				
13.	Duration of the trial				
	Date	Names	Signature		

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-VII: Clinical Trial Amendment Application Form (CTA-A)

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 2022		Department/Division/Office/U	Jnit	Pharmacovigilance and Food Safety Monitoring Division	
Document Type: Form				Doc. No	: FDISM/PVSM/FOM/xxx
	Cli	Clinical Trial Amendment Application		Revision Number	: 01
		Form (CTA-A)	Form (CTA-A)	Revision Date:	: 28/02/2023
Contraction of the second				Effective Date	: 28/02/2023
RWANDA FDA Rwanda Food and Drugs Authority				Review Due Date	: 28/02/2023
				Ref Doc.	: FDISM/PVSM/GDL/005

This form should be filled and signed by applicant for substantial amendment for an already approved clinical trial

A. DETAILS OF THE APPROVED ORIGINAL PROTOCOL		
Reference Number of the approved Clinical Trial		
Date of approval of original protocol (dd/mm/yyyy)		
Clinical Trial Title		
Principal Investigator approved for the clinical trial		
Number of sites approved for the clinical trial		
Number of subjects approved for the clinical trial		
Applicant of the current amendment (Sponsor or principal investigator)		
Contact person responsible for this application	First name:	
	Surname name:	
	E-mail:	
	Tel:	

B. SUMMARY OF PROPOSED CHANGES

Amendment title, number and natures supporting documentation: List of all types of supporting documents that you will submit

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023

Summary of current		Proposed change details:			
Reason/rationale for change(s): <i>Please provide the rationale for each of more than one.</i>	change if				
Multi-centre trials: <i>Will this amendment apply to all approved</i>	l site(s)?	□ YES □ NO			
If No: Specify the sites for which the an will apply	nendment				
C. DOCUMENTATION CHECKI	JIST				
Valid ethical approval of the proposed change(s)			□ YES		
Proof of payment of amendment fees as per Rwanda FDA regulations			□ YES	\Box NO	
Revised Protocol with version number (if applicable)			□ YES		
Other relevant supporting documentation in line with the amendment			□ YES		
Valid ethical approval of the proposed change(s)			□ YES		
D. DECLARATION (by applicant))				
I, (<i>Insert the Sponsor or PI</i>) the undersigned, hereby declare that I have submitted all required documentations, and have disclosed all information which may influence the approval of this application					
□ There are no changes being made other than those applied for in this submission, except for possible editorial changes. Any other changes will be applied for separately.					
\Box The information submitted is true and c	1				
Names:	Signatu	re:	Date:		

Names:	Signature:	Date:

Doc. No.: FDISM/PVSM/GDL/005	Revision Date: 01/04/2023	Review Due Date: 10/04/2026
Revision No.: 02	Approval date: 05/04/2023	Effective Date: 11/04/2023